GlassScriptPhysician profile
April Dawn Lockman
NPI 1134753569
$6,909.04
in general payments reported to CMS, 2019-2025
20 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,647 · 2022: $3,279 · 2023: $1,679 · 2024: $172 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,915.87 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,133.24 | 2021-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $585.39 | 2021-2023 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $501.07 | 2021-2023 | Entyvio, Gattex |
| Daiichi Sankyo INC. | $453.57 | 2021-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $314.78 | 2021-2023 | Rebyota, Cimzia |
| Ironwood Pharmaceuticals, INC | $311.15 | 2021-2023 | Linzess |
| Merz North America, INC. | $304.34 | 2024-2025 | |
| Celgene Corporation | $291.20 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $258.42 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $182.83 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $143.72 | 2021-2023 | Ocaliva |
| Pfizer INC. | $131.82 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $94.03 | 2021-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $87.64 | 2021-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $80.62 | 2021-2022 | |
| Braintree Laboratories, INC. | $55.96 | 2021 | |
| Genzyme Corporation | $28.72 | 2023 | |
| Ardelyx, INC. | $20.40 | 2023 | Ibsrela |
| Organon LLC | $14.27 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Lockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.